title: [The effect of donor specific blood transfusion (DST) on graft survival--intermittent coverage of cyclophosphamide].
abstract: Donor specific blood transfusion (DST), given prior to living related kidney transplantation has resulted in significant improvement in graft survival. This improvement, however, has been accomplished with a high rate of adverse sensitization against the donor. In an attempt to reduce the incidence of sensitization, we have employed DST with intermittent coverage of cyclophosphamide. A comparative study was done between 2 methods of DST with or without the coverage of immunosuppressant for prospective kidney transplant recipients from living related donors. In addition, the beneficial effect of DST on graft survival was evaluated in our recent series of living related transplantation using cyclosporine A (CsA) as postoperative immunosuppression. Twenty-nine prospective kidney transplant patients received 200 ml of fresh whole blood 3 times at 2 week intervals from HLA one-haploidentical living related donors. The first 13 patients received DST alone, while the remaining 16 were given cyclophosphamide (CPM 1.5 mg/kg/day) for 3 days prior to each DST. In patients with CPM coverage, 6.3% (1 of 16) developed positive T-warm antibody against donor and 15% of patients (2 of 13) with DST alone developed it. Like-wise 19% (3 of 16) of the former and 38% (5 of 13) of the latter became positive B-warm crossmatch. The difference in sensitization rates between these 2 groups was not statistically significant. Nineteen patients receiving DST were compared to 21 non-DST patients in incidence of acute rejection, graft function and graft survival with the same immunosuppressive regimen, such as CsA, prednisolone, and mizoribine.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Urology, Kitasato University School of Medicine.
authors.forename: I
authors.initials: I
authors.lastname: Kasai
authors.forename: K
authors.initials: K
authors.lastname: Kumano
authors.forename: M
authors.initials: M
authors.lastname: Iwamura
authors.forename: K
authors.initials: K
authors.lastname: Yoshida
authors.forename: S
authors.initials: S
authors.lastname: Mashimo
authors.forename: T
authors.initials: T
authors.lastname: Endo
authors.forename: T
authors.initials: T
authors.lastname: Saaki
authors.forename: K
authors.initials: K
authors.lastname: Koshiba
authors.forename: I
authors.initials: I
authors.lastname: Kikuo
authors.forename: H
authors.initials: H
authors.lastname: Uchida
mesh_terms: D000284:Administration, Oral; D001803:Blood Transfusion / Q000379:methods; D003520:Cyclophosphamide / Q000008:administration & dosage*; D003524:Cyclosporins / Q000008:administration & dosage; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology
chemical_list: D003524:Cyclosporins; D003520:Cyclophosphamide